AlzeCure Pharma AB (publ) announced that the company's presentation at the pain conference held by the Swedish Pain Society is now available in its entirety on the company's website. The presentation contains clinical data from the phase II study with the company's leading drug candidate in pain, ACD440, which is being developed for the treatment of peripheral neuropathic pain. The presentation, titled "Topical ACD440 Gel reduces pain induced by temperature-stimulation in patients with was held by Dr. Segerdahl and contains results from the recent neuropathic pain with sensory hypersensitivity", phase II clinical trial with ACD440.

Other co-authors of the material are Magnus Halldin, Rolf Karlsten, Karin Ellstrom and Adriana Miclescu. The Phase II study included fourteen patients, men and women aged 50-85 years with moderate to severe peripheral neuropathic pain. On average, the patients had pain for 4.75 years.

The results showed that after 7 days of treatment with ACD440, the temperature-triggered pain was reduced by about 50%, a significant and clinically relevant effect. No treatment-related side effects were reported, indicating that the product is safe and well tolerated by patients. AlzeCure's drug candidate ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain.

The discovery of TRPV1 that underlies the project was awarded the Nobel Prize in Physiology or Medicine in 2021. There is thus a strong scientific basis for this biological mechanism, including its relationship to pain signaling. ACD440 completed a positive phase Ib study in 2021.

It showed both very good tolerability and safety, but also a potent, long-lasting pain-relieving effect of the substance that is applied as a gel to the skin.